Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Malignant Melanoma

  Free Subscription


29.01.2018

1 Ann Surg Oncol
1 Br J Cancer
5 Br J Dermatol
1 Clin Cancer Res
1 Curr Opin Oncol
1 J Biol Chem
1 J Clin Invest
1 J Surg Oncol
3 Lancet Oncol
2 Melanoma Res
1 Ophthalmology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Surg Oncol

  1. MURTHA TD, Han G, Han D
    Predictors for Use of Sentinel Node Biopsy and the Association with Improved Survival in Melanoma Patients Who Have Nodal Staging.
    Ann Surg Oncol. 2018 Jan 24. pii: 10.1245/s10434-018-6348.
    PubMed     Text format     Abstract available


    Br J Cancer

  2. VAN LAAR R, Lincoln M, Van Laar B
    Development and validation of a plasma-based melanoma biomarker suitable for clinical use.
    Br J Cancer. 2018 Jan 23. pii: bjc2017477. doi: 10.1038/bjc.2017.
    PubMed     Text format     Abstract available


    Br J Dermatol

  3. BORSARI S, Pampena R, Benati E, Bombonato C, et al
    In vivo dermoscopic and confocal microscopy multi-step algorithm to detect in situ melanomas.
    Br J Dermatol. 2018 Jan 21. doi: 10.1111/bjd.16364.
    PubMed     Text format     Abstract available

  4. WEHNER MR
    Sunscreen and melanoma prevention: evidence and expectations.
    Br J Dermatol. 2018;178:15-16.
    PubMed     Text format    

  5. WIESNER T, Zbyszewski A
    Progress in the diagnosis and therapy of melanoma.
    Br J Dermatol. 2018;178:12-14.
    PubMed     Text format    

  6. MUTHIAH S, Tang D, Nasr B, Verykiou S, et al
    A new era in holistic care: bridging the gap between dermatologists and oncologists for the treatment of malignant melanoma.
    Br J Dermatol. 2018;178:1-4.
    PubMed     Text format    

  7. VERYKIOU S, Edwards N, Hill D
    How breakthroughs in translational research have impacted treatment strategies for melanoma.
    Br J Dermatol. 2018;178:5-8.
    PubMed     Text format    


    Clin Cancer Res

  8. ATKINS MB, Hodi FS, Thompson JA, McDermott D, et al
    Pembrolizumab plus pegylated interferon alfa-2b or ipilimumab for advanced melanoma or renal cell carcinoma: dose-finding results from the phase 1b KEYNOTE-029 study.
    Clin Cancer Res. 2018 Jan 22. pii: 1078-0432.CCR-17-3436.
    PubMed     Text format     Abstract available


    Curr Opin Oncol

  9. KOELBLINGER P, Thuerigen O, Dummer R
    Development of encorafenib for BRAF-mutated advanced melanoma.
    Curr Opin Oncol. 2018 Jan 18. doi: 10.1097/CCO.0000000000000426.
    PubMed     Text format     Abstract available


    J Biol Chem

  10. ZHAO T, Ding X, Yan C, Du H, et al
    Endothelial Rab7 GTPase mediates tumor growth and metastasis in lysosomal acid lipase-deficient mice.
    J Biol Chem. 2017;292:19198-19208.
    PubMed     Text format     Abstract available


    J Clin Invest

  11. VEATCH JR, Lee SM, Fitzgibbon M, Chow IT, et al
    Tumor infiltrating BRAFV600E-specific CD4 T cells correlated with complete clinical response in melanoma.
    J Clin Invest. 2018 Jan 23. pii: 98689. doi: 10.1172/JCI98689.
    PubMed     Text format     Abstract available


    J Surg Oncol

  12. CHU BS, Koffi W, Hoehn RS, Ertel A, et al
    Improvement and persistent disparities in completion lymph node dissection: Lessons from the National Cancer Database.
    J Surg Oncol. 2017;116:1176-1184.
    PubMed     Text format     Abstract available


    Lancet Oncol

  13. ASCIERTO PA, Eggermont AMM
    Neoadjuvant therapy in melanoma: the next step?
    Lancet Oncol. 2018 Jan 17. pii: S1470-2045(18)30016.
    PubMed     Text format    

  14. AMARIA RN, Prieto PA, Tetzlaff MT, Reuben A, et al
    Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
    Lancet Oncol. 2018 Jan 17. pii: S1470-2045(18)30015.
    PubMed     Text format     Abstract available

  15. BEAVER JA, Hazarika M, Mulkey F, Mushti S, et al
    Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis.
    Lancet Oncol. 2018 Jan 17. pii: S1470-2045(17)30846.
    PubMed     Text format     Abstract available


    Melanoma Res

  16. GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
    Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
    PubMed     Text format     Abstract available

  17. NARDIN C, Mateus C, Texier M, Lanoy E, et al
    Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
    Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
    PubMed     Text format     Abstract available


    Ophthalmology

  18. VAN POPPELEN NM, Vaarwater J, Mudhar HS, Sisley K, et al
    Genetic Background of Iris Melanomas and Iris Melanocytic Tumors of Uncertain Malignant Potential.
    Ophthalmology. 2018 Jan 19. pii: S0161-6420(17)32844.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: